1. Home
  2. STOK vs LMB Comparison

STOK vs LMB Comparison

Compare STOK & LMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STOK
  • LMB
  • Stock Information
  • Founded
  • STOK 2014
  • LMB 1901
  • Country
  • STOK United States
  • LMB United States
  • Employees
  • STOK N/A
  • LMB N/A
  • Industry
  • STOK Biotechnology: Pharmaceutical Preparations
  • LMB Engineering & Construction
  • Sector
  • STOK Health Care
  • LMB Consumer Discretionary
  • Exchange
  • STOK Nasdaq
  • LMB Nasdaq
  • Market Cap
  • STOK 1.3B
  • LMB 1.2B
  • IPO Year
  • STOK 2019
  • LMB 2014
  • Fundamental
  • Price
  • STOK $22.74
  • LMB $103.65
  • Analyst Decision
  • STOK Strong Buy
  • LMB Strong Buy
  • Analyst Count
  • STOK 6
  • LMB 3
  • Target Price
  • STOK $26.60
  • LMB $140.67
  • AVG Volume (30 Days)
  • STOK 893.3K
  • LMB 191.7K
  • Earning Date
  • STOK 11-04-2025
  • LMB 11-04-2025
  • Dividend Yield
  • STOK N/A
  • LMB N/A
  • EPS Growth
  • STOK N/A
  • LMB 35.95
  • EPS
  • STOK 0.91
  • LMB 2.92
  • Revenue
  • STOK $199,893,000.00
  • LMB $552,919,000.00
  • Revenue This Year
  • STOK $416.54
  • LMB $28.57
  • Revenue Next Year
  • STOK N/A
  • LMB $14.48
  • P/E Ratio
  • STOK $25.02
  • LMB $35.58
  • Revenue Growth
  • STOK 1218.82
  • LMB 8.06
  • 52 Week Low
  • STOK $5.35
  • LMB $63.02
  • 52 Week High
  • STOK $24.60
  • LMB $154.05
  • Technical
  • Relative Strength Index (RSI)
  • STOK 73.55
  • LMB 39.27
  • Support Level
  • STOK $18.80
  • LMB $97.69
  • Resistance Level
  • STOK $24.60
  • LMB $107.89
  • Average True Range (ATR)
  • STOK 1.23
  • LMB 5.60
  • MACD
  • STOK 0.02
  • LMB -0.39
  • Stochastic Oscillator
  • STOK 67.93
  • LMB 19.30

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

About LMB Limbach Holdings Inc.

Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.

Share on Social Networks: